Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy

NeuroReport

Volumn 21, Issue 6, 2010, Pages 457-462

  Ubhi, Kiren ^a   Rockenstein, Edward ^a   Mante, Michael ^a   Inglis, Chandra ^a   Adame, Anthony ^a   Patrick, Christina ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alpha synucleinopathy; Neurodegeneration; Oxidative stress

Indexed keywords

3 NITROPROPIONIC ACID; 3-NITROPROPIONIC ACID; ALPHA SYNUCLEIN; NITRO DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANIMAL; ARTICLE; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; NERVE CELL; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; SHY DRAGER SYNDROME; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MULTIPLE SYSTEM ATROPHY; NEURONS; NITRO COMPOUNDS; OXIDATIVE STRESS; PROPIONIC ACIDS;

EID: 77954941829     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0b013e328338ba6b     Document Type: Article

References (22)

1. Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 2005; 166:869-876. (Pubitemid 40315643)
2. Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol 1999; 56:90-94. (Pubitemid 29046914)
3. Nee LE, Gomez MR, Dambrosia J, Bale S, Eldridge R, Polinsky RJ. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1991; 1:9-13.
4. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, Marconi R, et al. Case-control study of multiple system atrophy. Mov Disord 2005; 20:158-163. (Pubitemid 40361118)
5. Norris EH, Giasson BI, Ischiropoulos H, Lee VM. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 2003; 278:27230-27240. (Pubitemid 36876880)
6. Ubhi K, Lee PH, Adame A, Inglis C, Mante M, Rockenstein E, et al. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. J Neurosci Res 2009; 87:2728-2739.
7. Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 2005; 25:10689-10699. (Pubitemid 41681917)
8. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004; 24:9434-9440. (Pubitemid 39426179)
9. Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008; 19:1271-1276.
10. Matsuura K, Kabuto H, Makino H, Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 1997; 73:45-48. (Pubitemid 27166123)
11. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al. Resistance of alpha-synuclein null mice to the Parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 2002; 99:14524-14529. (Pubitemid 35257704)
12. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 2004; 25:761-769. (Pubitemid 39013325)
13. Fountaine TM, Venda LL, Warrick N, Christian HC, Brundin P, Channon KM, et al. The effect of alpha-synuclein knockdown on MPP + toxicity in models of human neurons. Eur J Neurosci 2008; 28:2459-2473.
14. Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Hoglinger GU, et al. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 2008; 210:182-193. (Pubitemid 351265366)
15. Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alphasynuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem 2004; 89:1126-1136. (Pubitemid 38715830)
16. Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 2006; 21:541-548. (Pubitemid 43277537)
17. Jenner P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Pathol Biol (Paris) 1996; 44:57-64. (Pubitemid 26084783)
18. Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 2000; 157:1439-1445.
19. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290:985-989.
20. Ischiropoulos H. Oxidative modifications of alpha-synuclein. Ann N Y Acad Sci 2003; 991:93-100.
21. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 2002; 9:244-248. (Pubitemid 34261218)
22. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem 1995; 270:28257-28267.